The ban is appropriate for these peptides that have no data and all sorts of concerns regarding safety, said Dr Eric Topol, director and founder of the Scripps Research Translational Institute and author of Super Agers: An Evidence-Based Approach to Longevity
As depicted in the graph below, Virginia Medicaids gross spending on GLP-1s for weight loss increased from $3.9 million to $15.63 million per quarter since 2023
doi: 10.3389/fendo.2024.1366940
It provides appetite suppression, delayed gastric emptying, and glucose homeostasis through a single receptor pathway
We also discuss other treatment options
Similar content being viewed by others Background The introduction of sodium-glucose co-transporter 2 inhibitors (SGLT-2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and dipeptidyl peptidase-4 inhibitors (DPP-4i) has significantly advanced therapeutic strategies for managing type 2 diabetes mellitus (DM), offering improved glycemic control and notable cardiovascular and renal benefits [1,2,3]